Alfaxalone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Alfaxalone
Accession Number
DB11371
Type
Small Molecule
Groups
Vet Approved
Description

Alfaxalone, also known as alphaxalone or alphaxolone, is a neuroactive steroid and general anaesthetic. It is used in veterinary practice under the trade name Alfaxan, and is licensed for use in both dogs and cats. Along with alfadolone, it is also one of the constituents of anesthetic drug mixture althesin.

Structure
Thumb
Synonyms
Not Available
External IDs
GR 2/234 / GR-2/234
Categories
UNII
BD07M97B2A
CAS number
23930-19-0
Weight
Average: 332.484
Monoisotopic: 332.23514489
Chemical Formula
C21H32O3
InChI Key
DUHUCHOQIDJXAT-OLVMNOGESA-N
InChI
InChI=1S/C21H32O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)19(15)18(24)11-21(16,17)3/h13-17,19,23H,4-11H2,1-3H3/t13-,14+,15-,16+,17-,19+,20-,21+/m0/s1
IUPAC Name
(1S,2S,5R,7S,10S,11S,14S,15S)-14-acetyl-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-17-one
SMILES

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Alfaxalone.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Alfaxalone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Alfaxalone.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Alfaxalone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Alfaxalone.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Alaproclate.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Alfaxalone.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Alfaxalone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Alfaxalone.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Alfaxalone.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Alfaxalone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Alfaxalone.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alfaxalone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Alfaxalone.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Alfaxalone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Azaperone.Investigational, Vet Approved
AzelastineAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Alfaxalone.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Alfaxalone.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Alfaxalone.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Alfaxalone.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Alfaxalone.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Alfaxalone.Approved, Investigational
BuprenorphineAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Alfaxalone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Alfaxalone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Alfaxalone.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Alfaxalone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Alfaxalone.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Alfaxalone.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Alfaxalone.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Alfaxalone.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Alfaxalone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Alfaxalone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Alfaxalone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Alfaxalone.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Alfaxalone.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Alfaxalone.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Alfaxalone.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Alfaxalone.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Alfaxalone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Alfaxalone.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Alfaxalone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Alfaxalone.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alfaxalone.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Alfaxalone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Alfaxalone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Alfaxalone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Alfaxalone.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Alfaxalone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Alfaxalone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Alfaxalone.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Alfaxalone.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Alfaxalone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Alfaxalone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Alfaxalone.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Alfaxalone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Alfaxalone.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Alfaxalone.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Alfaxalone.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Alfaxalone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Alfaxalone.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Alfaxalone.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Alfaxalone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Alfaxalone.Approved
EthanolAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Alfaxalone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Alfaxalone.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Alfaxalone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Alfaxalone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Alfaxalone.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Alfaxalone.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Alfaxalone.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Alfaxalone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Alfaxalone.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Alfaxalone.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Alfaxalone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Alfaxalone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Alfaxalone.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Alfaxalone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Alfaxalone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Alfaxalone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Alfaxalone.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Alfaxalone.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Alfaxalone.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Alfaxalone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Alfaxalone.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Alfaxalone.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Alfaxalone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Alfaxalone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Alfaxalone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Alfaxalone.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Alfaxalone.Approved
HydrocodoneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Alfaxalone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Alfaxalone.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Alfaxalone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Alfaxalone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Alfaxalone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Alfaxalone.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Alfaxalone.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Alfaxalone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Alfaxalone.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Alfaxalone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Alfaxalone.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Alfaxalone.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Alfaxalone.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Alfaxalone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Alfaxalone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Alfaxalone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Alfaxalone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alfaxalone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Alfaxalone.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Alfaxalone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Alfaxalone.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Alfaxalone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Alfaxalone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Alfaxalone.Approved
MethotrimeprazineAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Alfaxalone.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Alfaxalone.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Alfaxalone.Approved
MetyrosineAlfaxalone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Alfaxalone.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Approved, Investigational
MirtazapineAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Alfaxalone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Alfaxalone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Alfaxalone.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Alfaxalone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Alfaxalone.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Alfaxalone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Alfaxalone.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Alfaxalone.Approved, Illicit
OrphenadrineAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Alfaxalone.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Alfaxalone.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Alfaxalone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Alfaxalone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Alfaxalone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Alfaxalone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Alfaxalone.Approved
ParaldehydeAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Alfaxalone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Alfaxalone.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Approved
PerazineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Alfaxalone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Alfaxalone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Alfaxalone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Alfaxalone.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Alfaxalone.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Alfaxalone.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Alfaxalone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Pomalidomide.Approved
PramipexoleAlfaxalone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Alfaxalone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Alfaxalone.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Alfaxalone.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Alfaxalone.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Alfaxalone.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alfaxalone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Alfaxalone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Alfaxalone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Alfaxalone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Alfaxalone.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Alfaxalone.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Alfaxalone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Alfaxalone.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Alfaxalone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Alfaxalone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Alfaxalone.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Alfaxalone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Romifidine.Vet Approved
RopiniroleAlfaxalone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Alfaxalone.Approved
RotigotineAlfaxalone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Alfaxalone.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alfaxalone.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Alfaxalone.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Alfaxalone.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alfaxalone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Alfaxalone.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Sultopride.Experimental
SuvorexantAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Alfaxalone.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Alfaxalone.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Alfaxalone.Investigational
ThalidomideAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Alfaxalone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Alfaxalone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Alfaxalone.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Alfaxalone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Alfaxalone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Alfaxalone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Alfaxalone.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Alfaxalone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Alfaxalone.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Alfaxalone.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Alfaxalone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Alfaxalone.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Alfaxalone.Approved
XenonThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Alfaxalone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Alfaxalone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Zolazepam.Vet Approved
ZolpidemAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Alfaxalone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Alfaxalone.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Alfaxalone.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Roan R: Use of alfaxalone in rabbits. Vet Rec. 2009 Feb 7;164(6):188. [PubMed:19202182]
  2. Strachan FA, Mansel JC, Clutton RE: A comparison of microbial growth in alfaxalone, propofol and thiopental. J Small Anim Pract. 2008 Apr;49(4):186-90. doi: 10.1111/j.1748-5827.2007.00473.x. Epub 2008 Jan 11. [PubMed:18194193]
  3. Vettorato E: Prolonged intravenous infusion of alfaxalone in a cat. Vet Anaesth Analg. 2013 Sep;40(5):551-2. doi: 10.1111/vaa.12044. Epub 2013 Apr 24. [PubMed:23611452]
  4. Herbert GL, Murison PJ: Eye position of cats anaesthetised with alfaxalone or propofol. Vet Rec. 2013 Apr 6;172(14):365. doi: 10.1136/vr.101404. Epub 2013 Feb 5. [PubMed:23385007]
  5. Goodwin W, Keates H, Pasloske K, Pearson M, Sauer B, Ranasinghe MG: Plasma pharmacokinetics and pharmacodynamics of alfaxalone in neonatal foals after an intravenous bolus of alfaxalone following premedication with butorphanol tartrate. Vet Anaesth Analg. 2012 Sep;39(5):503-10. doi: 10.1111/j.1467-2995.2012.00734.x. Epub 2012 May 30. [PubMed:22642499]
  6. Bertelsen MF, Sauer CD: Alfaxalone anaesthesia in the green iguana (Iguana iguana). Vet Anaesth Analg. 2011 Sep;38(5):461-6. doi: 10.1111/j.1467-2995.2011.00640.x. [PubMed:21831051]
  7. Jungck E, Kloss T, Blendl M, Hoerster W, Klaucke D: [Experiences with the steroid narcotic alfaxalone/alfadolone (Aurantex) in emergency patients in rescue service]. Anasth Intensivther Notfallmed. 1983 Feb;18(1):8-13. [PubMed:6846760]
  8. Brewster ME, Estes KS, Bodor N: Development of a non-surfactant formulation for alfaxalone through the use of chemically-modified cyclodextrins. J Parenter Sci Technol. 1989 Nov-Dec;43(6):262-5. [PubMed:2600731]
  9. Adami C, d'Ovidio D, Casoni D: Alfaxalone-butorphanol versus alfaxalone-morphine combination for immersion anaesthesia in oriental fire-bellied toads (Bombina orientalis). Lab Anim. 2015 Aug 25. pii: 0023677215601300. [PubMed:26306614]
  10. Tamura J, Ishizuka T, Fukui S, Oyama N, Kawase K, Itami T, Miyoshi K, Sano T, Pasloske K, Yamashita K: Sedative effects of intramuscular alfaxalone administered to cats. J Vet Med Sci. 2015 Aug;77(8):897-904. doi: 10.1292/jvms.14-0200. Epub 2015 Mar 19. [PubMed:25786416]
External Links
KEGG Drug
D07282
KEGG Compound
C13803
PubChem Compound
104845
PubChem Substance
347827976
ChemSpider
94637
BindingDB
50164570
ChEBI
34531
ChEMBL
CHEMBL190279
Wikipedia
Alfaxalone
ATC Codes
N01AX05 — Alfaxalone

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0242 mg/mLALOGPS
logP3.23ALOGPS
logP3.06ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)18.3ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity93.57 m3·mol-1ChemAxon
Polarizability38.64 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0ac1-3930000000-0197081ff727780b04f8

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 3-alpha-hydroxysteroids / 11-oxosteroids / Secondary alcohols / Ketones / Cyclic alcohols and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Progestogin-skeleton / 20-oxosteroid / 3-hydroxysteroid / 3-alpha-hydroxysteroid / Hydroxysteroid / Oxosteroid / 11-oxosteroid / Cyclic alcohol / Secondary alcohol / Ketone
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
corticosteroid hormone (CHEBI:34531)

Drug created on February 25, 2016 11:13 / Updated on December 01, 2017 16:19